Evolocumab has no effects on HFrEF injury biomarkers: the EVO-HF trial.

Antoni Bayés-GenísJosep LupónElena Revuelta-LopezCinta LlibrePaloma GastelurrutiaMar DomingoGermán CedielPau CodinaEvelyn Santiago-VacasDiego Rangel-SousaAgustín Fernández-CisnalGema MiñanaAnna MollarJulio Núñez

Published in: European journal of heart failure (2023)

Prospective randomized pilot trial, although with the limitation of the limited sample size, does not support the benefit of evolocumab in reducing troponin levels in patients with elevated LDL-C levels, history of CAD, and stable HFrEF. This article is protected by copyright. All rights reserved.

Keyphrases

phase iii
phase ii
open label
low density lipoprotein
coronary artery disease
clinical trial
study protocol
atrial fibrillation